Molecular profiling is driving precision oncology by enabling the classification of tumors based on their genomic makeup to diagnose and treat cancer. Clinicians can subject a patient's tissue or liquid biopsy to NGS to elucidate the patient's unique genomic profile. The profiling results can be used to identify targeted interventions that can be tailored to the patient such that ineffective treatments are avoided.
In this condensed tutorial, Vessel presents three real-world cases of patients with confirmed progressive disease in which liquid biopsy was used to identify actionable targets. The tutorial also includes a brief summary of the patient's history and the results of the liquid biopsy.